Executive Chairman and Chief Executive Officer - Miguel Martin Director of Strategic Finance and Investor Relations - Kevin Niland Operator: [Operator Instructions] This conference call is being recorded today, Wednesday, August 5, 2026. I would now like to turn the conference over to your host, Kevin Niland, Director of Strategic Finance and Investor Relations. Kevin Niland: Hello, and thank you for joining us.
With me are Miguel Martin, Executive Chairman and CEO, and Simona King, CFO. Earlier this morning, we filed our fiscal first quarter 2027 financials for the period ending June 30, 2026, and issued a news release containing our quarterly results. Financial statements, MD&A, and news releases are available on our IR website and can also be accessed via SEDAR+ and EDGAR.
In addition, you will find a supplemental information deck on our IR website. Please note that we present our financials in accordance with IFRS and in Canadian dollars. Throughout our discussions, we will be referring to both GAAP and non-GAAP adjusted results and encourage you to review the reconciliation contained within the press release from GAAP to the corresponding non-GAAP measures.
Our discussion today serves as a reminder that certain matters could constitute forward-looking statements that are subject to risks and uncertainties relating to our future financial or business performance. Actual results could differ materially from those anticipated in those forward-looking statements. Risk factors that may affect actual results are detailed in our annual information form and other periodic filings and registration statements.
Documents may similarly be accessed via SEDAR+ and EDGAR. Following our prepared remarks, we'll conduct a question-and-answer session with our covering analysts. With that, I'll turn the call over to Miguel.
Miguel Martin: Thanks, Kevin. Aurora has become synonymous with medical cannabis in nationally legal markets because we spent years building the infrastructure, scientific capability, and regulatory expertise required to deliver reliable, scalable, and consistently high-quality products to patients. A dedicated focus on medical cannabis enables us to maximize opportunities in the industry's most attractive, durable, and profitable segment, and should help us maintain and expand our leadership over time.
Extract — continue reading at the source.
